PARP Inhibitor Combination Approved for Metastatic Prostate Cancer Sensitive to Hormone Therapy
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for...
Progress Against Cancer
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for...
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S....
The combination therapy is approved for pre- and post-surgery bladder cancer treatment. The U.S. Food and Drug Administration (FDA)...
The FDA has converted the accelerated approval of tarlatamab-dlle to a full approval for previously treated adults with extensive-stage...
The FDA granted accelerated approval to sevabertinib for previously treated adults with HER2‑mutant non‑squamous non‑small cell lung cancer. The...
Daratumumab and hyaluronidase-fihj is now indicated as part of a combination therapy for the potentially fatal condition that can...
FDA expands selumetinib approval to include treatment of adults with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration...
The FDA approved epcoritamab-bysp as a monotherapy or with lenalidomide and rituximab for relapsed or refractory follicular lymphoma. The...